IRIS
PAOLICELLI, DAMIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.535
AS - Asia 3.567
EU - Europa 3.240
SA - Sud America 1.001
Continente sconosciuto - Info sul continente non disponibili 525
AF - Africa 266
OC - Oceania 9
Totale 18.143
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.238
SG - Singapore 1.372
IT - Italia 1.210
CN - Cina 807
BR - Brasile 773
HK - Hong Kong 465
RU - Federazione Russa 397
SE - Svezia 385
VN - Vietnam 304
DE - Germania 252
FR - Francia 229
GB - Regno Unito 203
FI - Finlandia 164
CA - Canada 139
UA - Ucraina 119
IN - India 111
CI - Costa d'Avorio 109
BD - Bangladesh 107
AR - Argentina 80
ID - Indonesia 64
NL - Olanda 58
JP - Giappone 53
ZA - Sudafrica 44
IQ - Iraq 43
MX - Messico 43
BE - Belgio 41
PK - Pakistan 38
VE - Venezuela 37
TR - Turchia 36
CO - Colombia 34
EC - Ecuador 32
ES - Italia 29
LT - Lituania 28
SA - Arabia Saudita 28
PL - Polonia 27
AT - Austria 24
PH - Filippine 24
TN - Tunisia 22
UZ - Uzbekistan 19
MA - Marocco 18
CL - Cile 15
JM - Giamaica 15
RO - Romania 14
CR - Costa Rica 13
EG - Egitto 13
GP - Guadalupe 13
SV - El Salvador 12
JO - Giordania 11
KE - Kenya 11
NI - Nicaragua 11
AE - Emirati Arabi Uniti 10
CW - ???statistics.table.value.countryCode.CW??? 9
HN - Honduras 9
MY - Malesia 9
PY - Paraguay 9
TT - Trinidad e Tobago 9
UY - Uruguay 9
AU - Australia 8
CZ - Repubblica Ceca 8
ET - Etiopia 8
OM - Oman 8
PR - Porto Rico 8
AZ - Azerbaigian 7
DZ - Algeria 7
IL - Israele 7
IR - Iran 7
KZ - Kazakistan 7
NP - Nepal 7
PA - Panama 7
SN - Senegal 7
AL - Albania 6
BO - Bolivia 6
DO - Repubblica Dominicana 6
IE - Irlanda 6
PE - Perù 6
BG - Bulgaria 5
GT - Guatemala 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
PT - Portogallo 5
CH - Svizzera 4
EU - Europa 4
HU - Ungheria 4
NG - Nigeria 4
SC - Seychelles 4
BS - Bahamas 3
DK - Danimarca 3
GR - Grecia 3
HR - Croazia 3
A1 - Anonimo 2
AO - Angola 2
BB - Barbados 2
EE - Estonia 2
KR - Corea 2
LB - Libano 2
MD - Moldavia 2
MK - Macedonia 2
MZ - Mozambico 2
RS - Serbia 2
RW - Ruanda 2
Totale 17.603
Salva come PNG Salva come JPEG
Città #
Ashburn 1.060
Fairfield 893
Singapore 727
San Jose 638
Woodbridge 603
Chandler 514
Hong Kong 464
Houston 430
Seattle 403
Milan 371
Cambridge 315
Wilmington 307
Nyköping 290
Beijing 261
Council Bluffs 228
Jacksonville 226
Ann Arbor 224
Dallas 185
New York 160
Los Angeles 147
Lauterbourg 139
Rome 126
Bari 122
Lawrence 118
Roxbury 114
Abidjan 109
Boardman 97
Ho Chi Minh City 97
Nanjing 94
Santa Clara 93
Helsinki 75
Des Moines 74
Princeton 70
Brooklyn 69
Buffalo 60
Columbus 60
São Paulo 59
Chicago 57
Munich 55
Hanoi 51
Tokyo 51
Inglewood 49
London 43
Brussels 40
Moscow 40
San Diego 40
Toronto 38
Frankfurt am Main 37
Jakarta 36
Orem 36
Montreal 35
Nuremberg 35
Falkenstein 34
Atlanta 33
Phoenix 28
Rio de Janeiro 28
Turin 27
Figino 25
Nanchang 25
Amsterdam 24
San Francisco 24
Shenyang 24
Guangzhou 22
Johannesburg 22
North Bergen 21
Norwalk 21
Warsaw 21
Belo Horizonte 20
Denver 20
Dong Ket 20
Baghdad 18
Naples 18
Paris 18
Tianjin 18
Vilnius 18
Bologna 17
Caracas 17
Chennai 17
Hebei 17
Jiaxing 17
Miami 15
Shanghai 15
Stockholm 15
Haiphong 14
Lahore 14
Poplar 14
Tashkent 14
Bisceglie 13
Boston 13
Brasília 13
Dhaka 13
Buenos Aires 12
Marseille 12
Palermo 12
Salt Lake City 12
Wuhan 12
Cagliari 11
Da Nang 11
Guayaquil 11
Jeddah 11
Totale 11.536
Salva come PNG Salva come JPEG
Nome #
Signs and symptoms of COVID-19 in patients with multiple sclerosis 248
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 242
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 238
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 214
A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B 201
Prognostic indicators in pediatric clinically isolated syndrome 195
Age-related changes of serum N-acetyl-aspartate in healthy controls. 194
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 194
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 193
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 190
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 188
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 187
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 182
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 181
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 180
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 179
Age-related disability in multiple sclerosis 175
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 174
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 167
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 166
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 165
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 163
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 158
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 156
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 154
Multiple Sclerosis Progression and Relapse Activity in Children 150
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 150
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 144
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 144
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. 142
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. 140
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 139
Atypical forms of Multiple Sclerosis or different phases of a same disease? 135
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 135
Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis 134
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 134
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 132
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 131
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 131
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 131
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 130
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 130
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 130
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 129
Geographical variations in sex ratio trends over time in multiple sclerosis. 128
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 127
A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP 126
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 126
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 125
Low serum urate levels are associated to female gender in multiple sclerosis patients. 125
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 125
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 124
Magnetoencephalography and high‐density electroencephalography study of acoustic event related potentials in early stage of multiple sclerosis: A pilot study on cognitive impairment and fatigue 124
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. 123
Predictors of disability worsening in clinically isolated syndrome 122
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 120
Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients 118
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 118
The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. 117
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 116
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. 116
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. 115
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 113
Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study 112
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 111
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 111
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 109
null 109
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 109
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 109
Variations of the perforin gene in patients with multiple sclerosis. 109
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 108
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 106
Coverage of the requirements of first and second level stroke unit in Italy 105
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 104
A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review 103
Informing MS patients on treatment options: a consensus on the process of consent taking 101
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 98
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy 98
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 98
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis 97
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 97
Enhancement is an age-related feature of multiple sclerosis lesions 96
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 95
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 95
Acoustic Voice Analysis as a Useful Tool to Discriminate Different ALS Phenotypes 95
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 94
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study) 94
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 93
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. 93
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 93
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 92
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia 90
An Internet- and Kinect-Based Multiple Sclerosis Fitness Intervention Training With Pilates Exercises: Development and Usability Study 90
The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. 90
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: A 18-month multicentre study 89
Immunomodulatory therapies delay disease progression in multiple sclerosis. 88
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. 88
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series 87
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 86
Totale 13.225
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.603
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.603
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022754 0 0 0 33 44 88 43 46 86 59 173 182
2022/20231.382 225 178 83 122 162 162 17 165 204 5 26 33
2023/2024461 57 66 28 29 37 108 13 18 8 23 6 68
2024/20252.782 133 42 180 102 75 246 257 223 133 166 424 801
2025/20266.424 842 357 436 736 652 360 642 213 664 593 222 707
2026/20271.672 217 277 391 787 0 0 0 0 0 0 0 0
Totale 18.143